SCHEMBL6501000

SCHEMBL6501000

CCCCCc1c(CC)nn2c(-c3ccc(Cl)cc3Cl)cc(SC)nc12

nearest known ligand 0.44

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 15/20 0.43
CNR2 P34972 2/20 0.38
CNR1 P21554 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071093 0.82 CRHR1 (0.43) CRHR1CNR2CNR1
SCHEMBL6495922 0.82 NPC1 (0.50) CRHR1CNR2CNR1
SCHEMBL6497711 0.81 NPC1 (0.49) CRHR1CNR2CNR1
SCHEMBL6500995 0.79 CRHR1 (0.41) CRHR1
SCHEMBL6495416 0.75 CRHR1 (0.44) CRHR1
SCHEMBL6497957 0.74 CRHR1 (0.43) CRHR1CNR2CNR1
SCHEMBL6504882 0.71 CRHR1 (0.50) CRHR1
SCHEMBL7048739 0.68 NPC1 (0.46) CRHR1
SCHEMBL6496618 0.68 MAPT (0.38) CRHR1
SCHEMBL6498696 0.68 CRHR1 (0.39) CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6958341-B2 Pyrazolopyrimidines as CRF antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-10-25 US claimed
US-6958341-B2 Pyrazolopyrimidines as CRF antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-10-25 US disclosed
US-20030139426-A1 Pyrazolopyrimidines as CRF antagonists WILDE RICHARD G (US) 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139426-A1 Pyrazolopyrimidines as CRF antagonists CRHR1, CRHR2, CRH CRHR1 1/4885CNR2 38/4885CNR1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.